Loading
Cellesce, in Cardiff, grows patient-derived tumour organoids, tiny three-dimensional copies of a patient's tumour, in bioreactors at a scale big enough for drug companies to test large numbers of compounds on them. It was bought by Molecular Devices in December 2022.
Cellesce is a Cardiff company providing contract development and manufacturing of large-scale patient-derived organoids for drug screening, using a bioprocess workflow and bioreactors that the Development Bank of Wales reports give 20- to 60-fold productivity gains. Companies House records it as incorporated on 12 April 2013, first named BBF Bio Limited. The Development Bank of Wales backed it from 2017, investing GBP 1 million across three rounds. In December 2022 Molecular Devices, LLC announced it had acquired Cellesce, and Companies House shows Molecular Devices (UK) Limited as the person with significant control from 5 December 2022, holding 75 per cent or more of shares and votes. Molecular Devices is not yet a company record in OnCo.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/